Sleep Apnea Devices Market: Growth and Competitor Trends

If you have been diagnosed with sleep apnea, or if you suspect you might have it, you are part of a very large group. Tens of millions of people worldwide are living with obstructive sleep apnea, or OSA. That is a condition where the airway partially or fully closes during sleep, disrupting breathing and dropping oxygen levels throughout the night. The devices used to treat and diagnose this condition have become a significant and fast-growing industry.

According to a 2025 competitor analysis report, the global sleep apnea devices market was valued at 6.47 billion dollars in 2024. It is projected to reach 12.23 billion dollars by 2033. That growth represents a compound annual growth rate of 7.32 percent over the forecast period.

What is driving that growth? Several things are working together.

Sleep apnea is more common than ever. Obesity, chronic stress, and sedentary lifestyles all increase the risk of developing OSA. According to a 2024 study cited in the report, an estimated 80.6 million Americans were projected to have OSA — roughly 47.6 million men and 33 million women. That is a large pool of people who need treatment.

Awareness is also rising. More people now understand that untreated sleep apnea is not just an inconvenience. It is linked to serious health problems including cardiovascular disease, stroke, hypertension, and diabetes. As that awareness grows, more people seek diagnosis and treatment. That increases demand for devices.

The devices themselves are improving. Newer CPAP machines are quieter, smaller, and easier to use. They connect to apps that let patients and clinicians track therapy data remotely. Better equipment means more patients stick with treatment, and more clinicians have reasons to recommend it.

Insurance coverage in the United States is also a factor. Favorable reimbursement policies for CPAP machines, masks, and oral appliances make treatment more financially accessible. That removes a barrier that has historically kept people from pursuing care.

The market is competitive. Major players include ResMed, Philips, Fisher and Paykel Healthcare, Somnomed, Drive DeVilbiss Healthcare, and several others. Each is investing in product development and global expansion. Recent activity in the space includes ResMed launching its AirSense 11 CPAP machine in India in early 2025, adding remote monitoring and a personal therapy assistant feature. Fisher and Paykel introduced a new nasal mask in Australia and New Zealand with improved comfort and quiet operation. Vivos Therapeutics, which makes FDA-approved oral appliance therapy for OSA, acquired the Sleep Center of Nevada — the largest sleep clinic operator in the state — in a nine million dollar deal that closed in April 2025.

Beyond CPAP, the market includes oral appliances, positional therapy devices, and surgical implant options. Each addresses a different patient profile. That variety matters because not every patient does well with CPAP. Roughly half of people prescribed CPAP therapy stop using it within the first year. The industry is responding by developing alternatives that are more comfortable and easier to integrate into daily life.

The United States leads the global market, driven by its high rate of OSA, strong clinical infrastructure, and broad insurance coverage. International markets are also expanding, particularly in Asia, where rising health awareness and healthcare investment are creating new demand.

For patients, this market activity translates into more choices. New products are entering the market. Competition is pushing companies to build devices that are easier to use and more effective. That is good news for the millions of people who need treatment and have struggled to find something that works for them.